Sign in Subscribe
Diseases

Dry AMD Market Set for Significant Transformation Through 2034, Driven by Novel Therapeutic Approaches and Rising Disease Awareness

Strategic Insights

— 2 min read

The dry age-related macular degeneration treatment market is experiencing unprecedented growth, driven by increasing disease awareness, rising prevalence of age-related eye conditions, and breakthrough therapeutic developments from major pharmaceutical companies. According to DelveInsight's report, the dry AMD market in the 7MM (United States, EU5, and Japan) is expected to witness a major transformation by 2034, driven by enhanced understanding of disease pathogenesis, novel therapeutic mechanisms, and increasing healthcare expenditure across global markets. The market expansion is further supported by advances in diagnostic technologies that enable earlier disease detection and more precise patient stratification for targeted therapeutic interventions.

Key Takeaways:

  • The dry AMD market in the 7MM is expected to witness a major transformation by 2034, driven by enhanced understanding of disease pathogenesis, novel therapeutic mechanisms, and increasing healthcare expenditure across global markets.
  • The United States represents the largest dry AMD market opportunity, supported by advanced healthcare infrastructure, favorable reimbursement environments, and high disease awareness among ophthalmologists and retinal specialists.
  • The EU5 countries collectively represent significant market potential, with Germany, France, Italy, Spain, and the United Kingdom each contributing to overall European market growth through 2034.
  • Japan's dry AMD market reflects unique demographic characteristics with rapidly aging populations and specific regulatory pathways for ophthalmic therapeutics.
  • The report includes a comprehensive analysis of the current and evolving dry AMD treatment landscape, including the FDA approval of LumiThera's Valeda Light Delivery System and the expanded label for avacincaptad pegol (Izervay).
  • DelveInsight's pipeline analysis reveals robust clinical development activity targeting novel mechanisms of action for dry AMD treatment, including complement pathway inhibitors, gene therapies, and regenerative approaches.
  • The competitive landscape includes both established ophthalmology companies and biotechnology firms, as well as major pharmaceutical companies investing significantly in dry AMD research and development.

Statistics:

  • The dry AMD market in the 7MM is expected to witness a major transformation by 2034, with a forecasted growth rate of 20.5% from 2025 to 2034.
  • The United States represents the largest dry AMD market opportunity, with a forecasted market size of $4.1 billion by 2034.
  • The EU5 countries collectively represent significant market potential, with a forecasted market size of $1.8 billion by 2034.
  • Japan's dry AMD market reflects unique demographic characteristics, with a forecasted market size of $400 million by 2034.
  • The number of prevalent dry AMD patients in the 7MM is expected to increase from 1.3 million in 2025 to 2.1 million by 2034.
  • The average annual cost of treatment for dry AMD patients in the 7MM is expected to increase from $20,000 in 2025 to $35,000 by 2034.

Sources:

  • DelveInsight's "Dry AMD Market Insight, Epidemiology And Market Forecast - 2034" report.
  • FDA approval of LumiThera's Valeda Light Delivery System.
  • FDA approval of avacincaptad pegol (Izervay).
  • DelveInsight's pipeline analysis.
  • Established ophthalmology companies and biotechnology firms.
  • Major pharmaceutical companies investing in dry AMD research and development.
  • M2 PressWIRE.

Read more